TECX

Tectonic Therapeutic, Inc. Common Stock
TECX

$18.36

0.49%

Market Cap: $271M

About: Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

36.08% more ownership

Funds ownership: 0% [Q1] → 36.08% (+36.08%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$49

167%

upside

Avg. target

$60

227%

upside

High target

$76

314%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Wells Fargo Tiago Fauth 63% 1-year accuracy 5 / 8 met price target	200%upside $55	Overweight Initiated	22 Aug 2024
Leerink Partners David Risinger 100% 1-year accuracy 4 / 4 met price target	167%upside $49	Outperform Initiated	24 Jul 2024
Piper Sandler Yasmeen Rahimi 52% 1-year accuracy 14 / 27 met price target	314%upside $76	Overweight Initiated	26 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about TECX published over the past 30 days

TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024

Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.

TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024

Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.

Tectonic Therapeutic to Participate in September Investor Conferences

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 million Cash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”, or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced its financial results for the second quarter ending June 30, 2024, and provided an overview of recent business highlights.

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapies Planned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024, with topline trial results expected in 2026 Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meeting Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 PH-HFpEF continues to enroll as planned, with topline study results expected in mid-2025 WATERTOWN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being evaluated for the treatment of patients with Group 2 PH-HFpEF.

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

See News Rankings